Bayer HealthCare Pharmaceuticals’ investigational radium-223 chloride has met the primary and secondary endpoints of a Phase III prostate cancer trial.
The randomised double-blind and placebo-controlled trial showed that radium-223 chloride improved overall survival in 44% of patients with castration-resistant prostate cancer and symptomatic bone metastases.
Go deeper with GlobalData
Radium-223 chloride demonstrated median overall survival of 14 months, compared to 11.2 months for the placebo group, a 49% improvement in time to prostate-specific antigen progression, and 33% of patients showed total alkaline phosphatise normalisation compared to 1% for placebo group.
The primary endpoint of the study was overall survival, while secondary endpoints included time to occurrence of SREs, changes and time to progression in prostate-specific antigen and alkaline phosphatise, safety and impact on quality of life measures.
Trial investigator Oliver Sartor said radium-223 chloride is the first bone-targeted, alpha-emitting radiopharmaceutical to demonstrate a survival benefit in men with castration-resistant prostate cancer and symptomatic bone metastases.
See Also:
The company plans to file a new drug application with the US Food and Drug Administration in mid-2012.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
